These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 38369678)

  • 1. Dose-effect relationships in neuroendocrine tumour liver metastases treated with [
    Ramdhani K; Beijer-Verduin J; Ebbers SC; van Rooij R; Smits MLJ; Bruijnen RCG; de Jong HWAM; Lam MGEH; Braat AJAT
    Eur J Nucl Med Mol Imaging; 2024 Jun; 51(7):2114-2123. PubMed ID: 38369678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose-Effect Relationships of
    van Roekel C; Bastiaannet R; Smits MLJ; Bruijnen RC; Braat AJAT; de Jong HWAM; Elias SG; Lam MGEH
    J Nucl Med; 2021 Feb; 62(2):272-279. PubMed ID: 32591491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Holmium-166 radioembolisation in patients with unresectable, chemorefractory liver metastases (HEPAR trial): a phase 1, dose-escalation study.
    Smits ML; Nijsen JF; van den Bosch MA; Lam MG; Vente MA; Mali WP; van Het Schip AD; Zonnenberg BA
    Lancet Oncol; 2012 Oct; 13(10):1025-34. PubMed ID: 22920685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor Dose Response in Yttrium-90 Resin Microsphere Embolization for Neuroendocrine Liver Metastases: A Tumor-Specific Analysis with Dose Estimation Using SPECT-CT.
    Chansanti O; Jahangiri Y; Matsui Y; Adachi A; Geeratikun Y; Kaufman JA; Kolbeck KJ; Stevens JS; Farsad K
    J Vasc Interv Radiol; 2017 Nov; 28(11):1528-1535. PubMed ID: 28888827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Additional holmium-166 radioembolisation after lutetium-177-dotatate in patients with neuroendocrine tumour liver metastases (HEPAR PLuS): a single-centre, single-arm, open-label, phase 2 study.
    Braat AJAT; Bruijnen RCG; van Rooij R; Braat MNGJA; Wessels FJ; van Leeuwaarde RS; van Treijen MJC; de Herder WW; Hofland J; Tesselaar MET; de Jong HWAM; Lam MGEH
    Lancet Oncol; 2020 Apr; 21(4):561-570. PubMed ID: 32112737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First Evidence for a Dose-Response Relationship in Patients Treated with
    Bastiaannet R; van Roekel C; Smits MLJ; Elias SG; van Amsterdam WAC; Doan D; Prince JF; Bruijnen RCG; de Jong HWAM; Lam MGEH
    J Nucl Med; 2020 Apr; 61(4):608-612. PubMed ID: 31601696
    [No Abstract]   [Full Text] [Related]  

  • 7. Efficacy of Radioembolization with
    Prince JF; van den Bosch MAAJ; Nijsen JFW; Smits MLJ; van den Hoven AF; Nikolakopoulos S; Wessels FJ; Bruijnen RCG; Braat MNGJA; Zonnenberg BA; Lam MGEH
    J Nucl Med; 2018 Apr; 59(4):582-588. PubMed ID: 28916623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Additional hepatic
    Braat AJAT; Kwekkeboom DJ; Kam BLR; Teunissen JJM; de Herder WW; Dreijerink KMA; van Rooij R; Krijger GC; de Jong HWAM; van den Bosch MAAJ; Lam MGEH
    BMC Gastroenterol; 2018 Jun; 18(1):84. PubMed ID: 29902988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. (⁹⁹m)Tc-MAA overestimates the absorbed dose to the lungs in radioembolization: a quantitative evaluation in patients treated with ¹⁶⁶Ho-microspheres.
    Elschot M; Nijsen JF; Lam MG; Smits ML; Prince JF; Viergever MA; van den Bosch MA; Zonnenberg BA; de Jong HW
    Eur J Nucl Med Mol Imaging; 2014 Oct; 41(10):1965-75. PubMed ID: 24819055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of factors affecting tumor response and survival in patients with primary and metastatic liver cancer treated with microspheres.
    Demirelli S; Erkilic M; Oner AO; Budak ES; Gunduz S; Ozgur O; Bozcuk H; Sindel HT; Boz A
    Nucl Med Commun; 2015 Apr; 36(4):340-9. PubMed ID: 25563137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term outcomes following 90Y Radioembolization of neuroendocrine liver metastases: evaluation of the radiation-emitting SIR-spheres in non-resectable liver tumor (RESiN) registry.
    Wong TY; Zhang KS; Gandhi RT; Collins ZS; O'Hara R; Wang EA; Vaheesan K; Matsuoka L; Sze DY; Kennedy AS; Brown DB
    BMC Cancer; 2022 Mar; 22(1):224. PubMed ID: 35232410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose-response relationship after yttrium-90-radioembolization with glass microspheres in patients with neuroendocrine tumor liver metastases.
    Ebbers SC; van Roekel C; Braat MNGJA; Barentsz MW; Lam MGEH; Braat AJAT
    Eur J Nucl Med Mol Imaging; 2022 Apr; 49(5):1700-1710. PubMed ID: 34873638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Holmium-166 Radioembolization in Hepatocellular Carcinoma: Feasibility and Safety of a New Treatment Option in Clinical Practice.
    Radosa CG; Radosa JC; Grosche-Schlee S; Zöphel K; Plodeck V; Kühn JP; Kotzerke J; Hoffmann RT
    Cardiovasc Intervent Radiol; 2019 Mar; 42(3):405-412. PubMed ID: 30603976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Partition Dosimetry and Outcomes of Metastatic Neuroendocrine Tumors after Yttrium-90 Resin Microsphere Radioembolization.
    Doyle PW; Workman CS; Grice JV; McGonigle TW; Huang S; Borgmann AJ; Baker JC; Taylor JE; Brown DB
    J Vasc Interv Radiol; 2024 May; 35(5):699-708. PubMed ID: 37871833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radioembolization for neuroendocrine liver metastases: safety, imaging, and long-term outcomes.
    Memon K; Lewandowski RJ; Mulcahy MF; Riaz A; Ryu RK; Sato KT; Gupta R; Nikolaidis P; Miller FH; Yaghmai V; Gates VL; Atassi B; Newman S; Omary RA; Benson AB; Salem R
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):887-94. PubMed ID: 22137020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship of Tumor Radiation-absorbed Dose to Survival and Response in Hepatocellular Carcinoma Treated with Transarterial Radioembolization with
    Hermann AL; Dieudonné A; Ronot M; Sanchez M; Pereira H; Chatellier G; Garin E; Castera L; Lebtahi R; Vilgrain V;
    Radiology; 2020 Sep; 296(3):673-684. PubMed ID: 32602828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radioembolization with
    Braat AJAT; Ahmadzadehfar H; Kappadath SC; Stothers CL; Frilling A; Deroose CM; Flamen P; Brown DB; Sze DY; Mahvash A; Lam MGEH
    Cardiovasc Intervent Radiol; 2020 Feb; 43(2):246-253. PubMed ID: 31646375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and laboratory toxicity after intra-arterial radioembolization with (90)y-microspheres for unresectable liver metastases.
    Smits ML; van den Hoven AF; Rosenbaum CE; Zonnenberg BA; Lam MG; Nijsen JF; Koopman M; van den Bosch MA
    PLoS One; 2013; 8(7):e69448. PubMed ID: 23894481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lung Mean Dose Prediction in Transarterial Radioembolization (TARE): Superiority of [
    Wagemans MEHM; Braat AJAT; van Rooij R; Smits MLJ; Bruijnen RCG; Prince JF; Bol GM; de Jong HWAM; Lam MGEH
    Cardiovasc Intervent Radiol; 2024 Apr; 47(4):443-450. PubMed ID: 38326577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Feasibility of high activity rhenium-188-microsphere in hepatic radioembolization.
    Liepe K; Brogsitter C; Leonhard J; Wunderlich G; Hliscs R; Pinkert J; Folprecht G; Kotzerke J
    Jpn J Clin Oncol; 2007 Dec; 37(12):942-50. PubMed ID: 18094017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.